2150 St. ElzEar Boulevard West
Laval, QC H7L 4A8
Industry: Drug Manufacturers—Specialty & Generic
Full Time Employees: 19,600
|Mr. Thomas J. Appio||CEO & Director||2.9M||N/A||1962|
|Mr. Thomas G. Vadaketh||Exec. VP & CFO||N/A||N/A||1963|
|Mr. Mirza Dautbegovic||Sr. VP & COO||N/A||N/A||N/A|
|Mr. John S. Barresi||Sr. VP, Controller & Chief Accounting Officer||N/A||N/A||1973|
|Dr. Robert F. Butz||VP of Medical & Scientific Affairs||N/A||N/A||N/A|
|Mr. Arthur J. Shannon||Sr. VP and Head of Investor Relations & Global Communications||N/A||N/A||N/A|
|Ms. Seana Carson||Exec. VP & Gen. Counsel||N/A||N/A||1972|
|Ms. Kathleen Fitzpatrick||Sr. VP & Chief HR Officer||N/A||N/A||N/A|
|Dr. Tage Ramakrishna M.D.||Chief Medical Officer and Pres of R&D||N/A||N/A||1974|
|Mr. Jeff Hartness||Sr. VP of Market Access, Commercial Operations & Gov. Affairs||N/A||N/A||N/A|
Bausch Health Companies Inc., together with its subsidiaries, develops, manufactures, and markets a range of pharmaceutical, medical device, and over-the-counter (OTC) products primarily in the therapeutic areas of eye health, gastroenterology, and dermatology. The company operates through five segments: Bausch + Lomb, Salix, International Rx, Ortho Dermatologics, and Diversified Products. The Bausch + Lomb segment offers products with a focus on the vision care, surgical, and consumer, surgical, and ophthalmic pharmaceuticals products. The Salix segment provides gastroenterology products in the United States. The International Rx segment offers Solta products, branded and generic pharmaceutical products, OTC products, and medical device products, and Bausch + Lomb products in Canada, Europe, Asia, Australia, Latin America, Africa, and the Middle East. The Ortho Dermatologics segment provides dermatological products in the United States; and Solta medical aesthetic devices internationally. The Diversified Products segment offers pharmaceutical products in the areas of neurology and other therapeutic classes, as well as generic and dentistry products in the United States. The company was formerly known as Valeant Pharmaceuticals International, Inc. and changed its name to Bausch Health Companies Inc. in July 2018. Bausch Health Companies Inc. is headquartered in Laval, Canada.
Bausch Health Companies Inc.’s ISS Governance QualityScore as of February 1, 2023 is 5. The pillar scores are Audit: 4; Board: 3; Shareholder Rights: 3; Compensation: 8.